PMID- 18030207
OWN - NLM
STAT- MEDLINE
DCOM- 20080118
LR  - 20151119
IS  - 1536-4801 (Electronic)
IS  - 0277-2116 (Linking)
VI  - 45
IP  - 4
DP  - 2007 Oct
TI  - Proton pump inhibitor utilization patterns in infants.
PG  - 421-7
AB  - OBJECTIVE: Practice patterns regarding pediatric gastroesophageal reflux disease 
      include acid suppression for infants meeting certain clinical criteria. This 
      study aimed to examine the use of proton pump inhibitors (PPI) in infants and 
      neonates. PATIENTS AND METHODS: This retrospective observational study used data 
      from 1999 to 2004 from 4 health care plans in the United States. Infants age <12 
      months with at least 1 pharmacy claim for a PPI were identified. Demographic 
      information and PPI utilization patterns were assessed. Medical charts were 
      reviewed in a subset of patients to gather dosing information. RESULTS: 
      Identified infants (N = 2469) were 58% male. PPI use rose 4-fold from 2000 to 
      2003; lansoprazole and omeprazole were almost exclusively used. Treatment for 
      almost half of the patients was initiated by their fourth month of life. The most 
      common diagnoses identified through medical claims included gastroesophageal 
      reflux (59%), problems feeding (23%), upper respiratory infections (23%), 
      esophagitis (21%), and pain from gas (20%). Preindex H2 blockade was evident in 
      58% of the patients; preindex metoclopramide was used in 38% of the patients. 
      Longer duration of PPI therapy was associated with patients who had more 
      comorbidities. Through chart review of 388 patients, a subset of 272 patients 
      with dosing information revealed that a median daily dosage in patients receiving 
      lansoprazole was 1.74 mg . kg . day compared with 1.21 mg . kg . day for 
      omeprazole. CONCLUSIONS: PPI use in the study population increased steadily from 
      1999 to 2004. These data offer valuable information on current PPI dosing 
      patterns that may be used to design future clinical trials for assessment of 
      gastroesophageal reflux disease regimens and clinical outcomes in the infant 
      population.
FAU - Barron, John J
AU  - Barron JJ
AD  - HealthCore, Inc, Wilmington, DE, USA. jbarron@healthcore.com
FAU - Tan, Hiangkiat
AU  - Tan H
FAU - Spalding, James
AU  - Spalding J
FAU - Bakst, Alan W
AU  - Bakst AW
FAU - Singer, Joseph
AU  - Singer J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pediatr Gastroenterol Nutr
JT  - Journal of pediatric gastroenterology and nutrition
JID - 8211545
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
CIN - J Pediatr Gastroenterol Nutr. 2007 Oct;45(4):395-8. PMID: 18030202
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
MH  - Age Factors
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Drug Administration Schedule
MH  - *Drug Utilization Review
MH  - Female
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Insurance, Pharmaceutical Services
MH  - Lansoprazole
MH  - Male
MH  - Medical Audit
MH  - Omeprazole/therapeutic use
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Proton Pump Inhibitors/economics/*therapeutic use
MH  - Retrospective Studies
MH  - United States
EDAT- 2007/11/22 09:00
MHDA- 2008/01/19 09:00
CRDT- 2007/11/22 09:00
PHST- 2007/11/22 09:00 [pubmed]
PHST- 2008/01/19 09:00 [medline]
PHST- 2007/11/22 09:00 [entrez]
AID - 00005176-200710000-00006 [pii]
AID - 10.1097/MPG.0b013e31812e0149 [doi]
PST - ppublish
SO  - J Pediatr Gastroenterol Nutr. 2007 Oct;45(4):421-7. doi: 
      10.1097/MPG.0b013e31812e0149.